Claims for Patent: 7,179,834

Summary for Patent: 7,179,834

Title:	Salinosporamides and methods for use thereof
Abstract:	The present invention is based on the discovery that certain fermentation products of the marine actinomycete strains CNB392 and CNB476 are effective inhibitors of hyperproliferative mammalian cells. The CNB392 and CNB476 strains lie within the family Micromonosporaceae, and the generic epithet Salinospora has been proposed for this obligate marine group. The reaction products produced by this strain are classified as salinosporamides, and are particularly advantageous in treating neoplastic disorders due to their low molecular weight, low IC.sub.50 values, high pharmaceutical potency, and selectivity for cancer cells over fungi.
Inventor(s):	Fenical; William (Del Mar, CA), Jensen; Paul (San Diego, CA), Mincer; Tracy (San Diego, CA), Feling; Robert H. R. (La Jolla, CA)
Assignee:	The Regents of the University of California (Oakland, CA)
Application Number:	10/600,854
Patent Claims:	1. A pharmaceutical composition, comprising an effective amount of a compound having the structure (I) and a pharmaceutically acceptable carrier: ##STR00004## wherein R.sub.1 to R.sub.3 are each independently --H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substitued heterocyclic, cycloalkyl, substitued cycloalkyl, alkoxy, substituted alkoxy, thioalkyl, substituted thioalkyl, hydroxy, halogen, amino, amido, carboxyl, --C(O)H, acyl, oxyacyl, carbamate, sulfonamide, or sulfuryl, each R.sub.4 is independently alkyl, substitued alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substitued aryl, cycloalkyl, substitued cycloalkyl, E.sub.1 to E.sub.4 are each independently --O, --NR.sub.5, or --S, wherein R.sub.5 is --H or C.sub.1 C.sub.6 alkyl, and x is 0 to 8, and further comprising at least one additional anti-neoplastic agent other than the compound having the structure (I). 2. The composition of claim 1, wherein E.sub.1, E.sub.3, and E.sub.4 are --O, and E.sub.2 is --NH. 3. The composition of claim 1, wherein R.sub.1 and R.sub.2 are --H, alkyl, or substituted alkyl, and R.sub.3 is hydroxy or alkoxy. 4. The composition of claim 1, wherein R.sub.1 is substituted alkyl. 5. The composition of claim 4, wherein the substituted alkyl is a halogenated alkyl. 6. The composition of claim 5, wherein the halogenated alkyl is a chlorinated alkyl. 7. The composition of claim 1, wherein the anti-neoplastic agent comprises an antimetabolite, an alkylating agent, a plant alkaloid, an antibiotic, a hormone, or an enzyme. 8. The composition of claim 7, wherein the antimetabolite is selected from a group consisting of methotrexate, 5-fluorouracil, 6-mercaptopurine, cytosine arabinoside, hydroxyurea, and 2-chlorodeoxyadenosine. 9. The composition of claim 7, wherein the alkylating agent is selected from a group consisting of cyclophosphamide, melphalan, busulfan, paraplatin, chlorambucil, and nitrogen mustard. 10. The composition of claim 7, wherein the plant alkaloid is selected from a group consisting of vincristine, vinblastine, taxol, and etoposide. 11. The composition of claim 7, wherein the antibiotic is selected from a group consisting of doxorubicin (adriamycin), daunorubicin, mitomycin c, and bleomycin. 12. The composition of claim 7, wherein the hormone is selected from a group consisting of calusterone, diomostavolone, propionate, epitiostanol, mepitiostane, testolactone, tamoxifen, polyestradiol phosphate, megesterol acetate, flutamide, nilutamide, and trilotane. 13. The composition of claim 7, wherein the enzyme is selected from a group consisting of L-asparaginase derivatives and aminoacridine derivatives. 14. The composition of claim 13, wherein the aminoacridine derivative is amsacrine. 15. An article of manufacture comprising packaging material and a pharmaceutical composition contained within said packaging material, wherein said packaging material comprises a label which indicates that said pharmaceutical composition can be used for treatment of a cell proliferative disorder and wherein said pharmaceutical composition comprises at least one compound having the structure (I): ##STR00005## wherein: R.sub.1 to R.sub.3 are each independently --H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, cycloalkyl, substituted cycloalkyl, alkoxy, substituted alkoxy, thioalkyl, substituted thioalkyl, hydroxy, halogen, amino, amido, carboxyl, --C(O)H, acyl, oxyacyl, carbamate, sulfonamide, or sulfuryl, each R.sub.4 is independently alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, E.sub.1 to E.sub.4 are each independently --O, --NR.sub.5, or --S, wherein R.sub.5 is --H or C.sub.1 C.sub.6 alkyl, and x is 0 to 8, wherein the cell proliferative disorder is colon cancer. 16. The article of manufacture of claim 15, wherein E.sub.1, E.sub.3, and E.sub.4 are --O, and E.sub.2 is --NH. 17. The article of manufacture of claim 15, wherein R.sub.1 and R.sub.2 are --H, alkyl, or substituted alkyl, and R.sub.3 is hydroxy or alkoxy. 18. The article of manufacture of claim 15, wherein R.sub.1 is substituted alkyl. 19. The article of manufacture of claim 18, wherein the substituted alkyl is a halogenated alkyl. 20. The article of manufacture of claim 19, wherein the halogenated alkyl is a chlorinated alkyl. 21. A pharmaceutical composition, comprising an effective amount of a compound having the structure (I) and a pharmaceutically acceptable carrier: ##STR00006## wherein: R.sub.1 to R.sub.3 are each independently --H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, cycloalkyl, substituted cycloalkyl, alkoxy, substituted alkoxy, thioalkyl, substituted thioalkyl, hydroxy, halogen, amino, amido, carboxyl, --C(O)H, acyl, oxyacyl, carbamate, sulfonamide, or sulfuryl, each R.sub.4 is independently alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, E.sub.1 to E.sub.4 are each independently --O, --NR.sub.5, or --S, wherein R.sub.5 is --H or C.sub.1 C.sub.6 alkyl, and x is 0 to 8, and further comprising at least one additional anti-neoplastic agent, wherein the composition is useful for treatment of colon cancer. 22. The composition of claim 21, wherein E.sub.1, E.sub.3, and E.sub.4 are --O, and E.sub.2 is --NH. 23. The composition of claim 21, wherein R.sub.1 and R.sub.2 are --H, alkyl, or substituted alkyl, and R.sub.3 is hydroxy or alkoxy. 24. The composition of claim 21, wherein R.sub.1 is substituted alkyl. 25. The composition of claim 24, wherein the substituted alkyl is a halogenated alkyl. 26. The composition of claim 25, wherein the halogenated alkyl is a chlorinated alkyl. 27. The composition of claim 21, wherein the anti-neoplastic agent comprises an antimetabolite, an alkylating agent, a plant alkaloid, an antibiotic, a hormone, or an enzyme. 28. The composition of claim 27, wherein the antimetabolite is selected from a group consisting of methotrexate, 5-fluorouracil, 6-mercaptopurine, cytosine arabinoside, hydroxyurea, and 2-chlorodeoxyadenosine. 29. The composition of claim 27, wherein the alkylating agent is selected from a group consisting of cyclophosphamide, melphalan, busulfan, paraplatin, chlorambucil, and nitrogen mustard. 30. The composition of claim 27, wherein the plant alkaloid is selected from a group consisting of vincristine, vinblastine, taxol, and etoposide. 31. The composition of claim 27, wherein the antibiotic is selected from a group consisting of doxorubicin (adriamycin), daunorubicin, mitomycin c, and bleomycin. 32. The composition of claim 27, wherein the hormone is selected from a group consisting of calusterone, diomostavolone, propionate, epitiostanol, mepitiostane, testolactone, tamoxifen, polyestradiol phosphate, megesterol acetate, flutamide, nilutamide, and trilotane. 33. The composition of claim 27, wherein the enzyme is selected from a group consisting of L-asparaginase derivatives and aminoacridine derivatives. 34. The composition of claim 33, wherein the aminoacridine derivative is amsacrine.

Details for Patent 7,179,834

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2022-06-24